Press Releases

Juvenescence announces a partnership with Evgen Pharma PLC to license its sulforaphane Sulforadex® stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.

Relation Therapeutics, announces Project RE, which will apply Relation Therapeutics’ and its partners’ technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19.

LyGenesis, a clinical-stage biotechnology company announced today the publication of a new peer-reviewed paper published in journal Hepatology on its organ regeneration technology.

Juvenescence Limited and G3 Therapeutics announced the formation of Juvenomics Limited, a joint venture between the two parent companies.

AgeX, a Juvenescence partner, and Sernova collaborate to utilize AgeX’s UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for the treatment of type I diabetes and hemophilia A.

AgeX Therapeutics, a Juvenescence partner, announced that ImStem Biotechnology has received notification from the FDA that it has cleared the investigational New Drug application to evaluate IMS001 for the treatment...

Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform. Goal of developing cellular therapies for Huntington’s disease and potentially Parkinson’s, Alzheimer’s and other neurological conditions. Builds on...

AgeX, a Juvenescence partner, announced a research collaboration with a Japanese biopharma company utilizing AgeX’s HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.

NetraMark Corp. and Juvenescence are excited to announce the extension of their collaboration agreement to include drug repurposing and drug discovery.

At the end of its first year as a public company, Juvenescence partner AgeX issues a letter shareholders reflecting on progress made, as well as current initiatives and future plans.

AgeX Therapeutics, a biotechnology company, and Juvenescence, a biotech longevity company, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine.

LyGenesis, a Juvenescence partner, focused on organ regeneration, announced that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, and the Longevity Vision...